{
    "info": {
        "nct_id": "NCT06450041",
        "official_title": "Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFβi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial",
        "inclusion_criteria": "* Patients must be ≥ 1 year and ≤31 years of age at the time of enrollment on the study.\n* Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.\n* Patients must have high-risk neuroblastoma according to COG risk classification at the time of study registration. Patients whose disease was initially considered low or intermediate risk but then reclassified as high-risk neuroblastoma prior to enrollment also meet this criteria.\n* Patients must have at least ONE of the following:\n\n  1) Recurrent/progressive disease after the diagnosis of high risk neuroblastoma at any time prior to enrollment - regardless of response to frontline therapy. (Note that this excludes patients initially considered low or intermediate risk that progressed to high risk disease but have not progressed after the diagnosis of high risk neuroblastoma).\n\n  2) If no prior history of recurrent/progressive disease since the diagnosis of high-risk neuroblastoma,\n\n  2a) Refractory disease: A best overall response of no response/stable disease since diagnosis of high-risk neuroblastoma AND after at least 4 courses of induction therapy.\n\n  2b) Persistent disease: A best overall response of partial response since diagnosis of high-risk neuroblastoma AND after at least 4 courses of induction therapy\n* Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below) based on institutional assessment:\n\n  1) Bone Sites\n  1. a) MIBG avid tumors: patients must meet one of the following criteria:\n\n     a. Patients with recurrent/progressive or refractory disease: i. Must have at least one MIBG avid bone site on planar imaging OR ii. Must have > 2 avid bone lesions on SPECT. iii. A biopsy is not required unless the above imaging criteria are not met. b. Patients with persistent disease: i. If a patient has 3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then no biopsy is required.\n\n     ii. If a patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone) then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Bone lesions may be biopsied at any time point prior to enrollment.\n\n  1b) For MIBG non-avid tumors, patients must have biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma from a lesion at any time prior to enrollment of at least one site (with or without FDG-PET uptake).\n\n  2) Bone Marrow Any amount of tumor cells in the bone marrow (including neuroblasts, mature and maturing ganglion cells) done at the time of study enrollment based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and biopsies.\n\n  3) Soft Tissue Sites\n\n  3a) At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:\n  1. SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm, or for discrete lymph nodes ≥ 15mm on short axis. Lesions meeting size criteria will be considered measurable.\n  2. In addition to size, a lesion needs to meet ONE of the following criteria except for patients with parenchymal CNS lesions which will only need to meet size criteria:\n\n     1. For MIBG avid tumors: lesion must be MIBG avid and meet one of the following criteria:\n\n  <!-- -->\n\n  1. For patients with recurrent/progressive or refractory disease:\n\n     i. No biopsy is required\n  2. For patients with persistent disease:\n\n     i. If a patient has 3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then no biopsy is required.\n\n     ii. If a patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Soft tissue lesions may be biopsied at any time point prior to enrollment.\n\n     b. For MIBG non-avid tumors, patient must have biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment from soft tissue lesion (with or without FDG uptake) present at time of enrollment.\n\n  3b) At least one non-target soft tissue lesion that is not measurable, but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment OR is MIBG avid on planar imaging.\n* Patients must have a Lansky (≤ 16 years) or Karnofsky (> 16 years) score of ≥ 50 (Appendix I).\n\nNote: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.\n\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study registration.\n* Patients must not have received the therapies indicated below after disease evaluation or within the specified time period prior to registration on this study as follows:\n\n  1. Myelosuppressive chemotherapy: must not have received within 2 weeks prior to registration.\n  2. Biologic anti-neoplastics- agents not known to be associated with reduced platelet or ANC counts (including retinoids): must not have received within 7 days prior to registration.\n  3. Monoclonal antibodies: must not have received last dose within 14 days of registration and resolution of all toxicities.\n  4. Cellular Therapy (e.g. modified T cells, NK cells, dentritic cells etc.): must not have received within 3 weeks and resolution of all toxicities.\n  5. Radiation: must not have received small port radiation within 7 days prior to registration, large field radiation within 12 weeks, and 131I-MIBG therapy or other radiopharmaceutical within 6 weeks.\n  6. Hematopoietic Stem Cell Transplant- none following myeloblative therapy within 6 weeks\n  7. Any other investigational agents (covered under another IND within 14 days\n  8. Strong inducers or inhibitors of CYP3A4\n* Hematologic Function:\n\nNOTE: No short acting hematopoietic growth factors within 7 days of blood draw documenting eligibility and no long-acting hematopoietic growth factors within 14 days of blood draw documenting eligibility\n\n1. Absolute Neutrophil count ≥750/µL\n2. Platelet count ≥ 75,000/µL, transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)\n\nPatients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria above.\n\n* Renal Function Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age\n* Liver Function\n\n  1. Total bilirubin ≤ 1.5 x ULN for age; and,\n  2. SGPT (ALT) ≤ 135 U/L (≤ 3x ULN). Note that for ALT, the upper limit of normal for all sites is defined as 45 U/L.\n* Cardiac Function\n\n  1. Normal ejection fraction (≥ 55%) documented by either echocardiogram OR\n  2. Normal fractional shortening (≥ 27%) documented by echocardiogram\n* Pulmonary Function No evidence of dyspnea at rest\n* Reproductive Function All females ≥ Tanner stage 2 and post-menarchal of childbearing potential must have a negative beta-HCG within 7 days prior to study registration. Males and females of reproductive age and childbearing potential must commit to using effective contraception for the duration of their participation.\n* Central Nervous System (CNS) Patients with a history of intraparenchymal or leptomeningeal based CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.\n\nPatients with skull-based tumors with direct intracranial extension are eligible as long as there are no neurologic signs or symptoms related to the lesion.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 31 Years",
        "exclusion_criteria": "* Patients who are pregnant, breast feeding, or unwilling to use effective contraception during the study\n* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.\n* Patients with disease of any major organ system that would compromise their ability to withstand therapy.\n* Patients with > Grade 2 diarrhea.\n* Patients who have undergone a prior allogeneic stem cell or solid organ transplant.\n* Patients who are on hemodialysis.\n* Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture negative, afebrile, and meet other organ function criteria.\n* Patients with known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.\n* Patients must not have been diagnosed with any other malignancy.\n* Patients with history of Grade 4 Allergic reactions to anti-GD2 antibody therapy or reactions that caused permanent discontinuation of therapy.\n* Patients with history of progressive disease while receiving therapy per ANBL1221.\n* Patient declines participation in the NANT biology study and the site has not been granted a waiver from participation.\n* Systemic Steroids and Immunosuppressive Medications\n* Patients who have received pharmacologic doses of systemic steroids 7 days prior to study registration or likely to require them after study registration.\n\nNote: Exceptions are the following:\n\n1. Patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration.\n2. The use of conventional doses of inhaled steroids for the treatment of asthma\n3. The use of physiologic doses of steroids for patients with known adrenal insufficiency.\n\n   * Patients on any other immunosuppressive medications (e.g., cyclosporine, tacrolimus) at the time of study registration.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "2) Bone Marrow Any amount of tumor cells in the bone marrow (including neuroblasts, mature and maturing ganglion cells) done at the time of study enrollment based on routine morphology and/or immunohistochemistry in at least one sample from bilateral aspirates and biopsies.",
            "criterions": [
                {
                    "exact_snippets": "Any amount of tumor cells in the bone marrow (including neuroblasts, mature and maturing ganglion cells)",
                    "criterion": "tumor cells in bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "done at the time of study enrollment",
                    "criterion": "bone marrow assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "based on routine morphology and/or immunohistochemistry",
                    "criterion": "bone marrow assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": [
                                "routine morphology",
                                "immunohistochemistry"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "in at least one sample from bilateral aspirates and biopsies",
                    "criterion": "bone marrow sample source",
                    "requirements": [
                        {
                            "requirement_type": "sample source",
                            "expected_value": "at least one sample from bilateral aspirates and biopsies"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. For patients with persistent disease:",
            "criterions": [
                {
                    "exact_snippets": "patients with persistent disease",
                    "criterion": "persistent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac Function",
            "criterions": [
                {
                    "exact_snippets": "Cardiac Function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "sufficient"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1) Bone Sites",
            "criterions": [
                {
                    "exact_snippets": "Bone Sites",
                    "criterion": "bone sites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. For patients with recurrent/progressive or refractory disease:",
            "criterions": [
                {
                    "exact_snippets": "recurrent/progressive or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "recurrent",
                                "progressive",
                                "refractory"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver Function",
            "criterions": [
                {
                    "exact_snippets": "Liver Function",
                    "criterion": "liver function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "adequate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Monoclonal antibodies: must not have received last dose within 14 days of registration and resolution of all toxicities.",
            "criterions": [
                {
                    "exact_snippets": "Monoclonal antibodies: must not have received last dose within 14 days of registration",
                    "criterion": "monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "resolution of all toxicities",
                    "criterion": "toxicities from monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. If a patient has 3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then no biopsy is required.",
            "criterions": [
                {
                    "exact_snippets": "3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone)",
                    "criterion": "MIBG avid sites",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": "sites"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "planar imaging",
                                "SPECT imaging"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "no biopsy is required",
                    "criterion": "biopsy requirement",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria above.",
            "criterions": [
                {
                    "exact_snippets": "known bone marrow metastatic disease",
                    "criterion": "bone marrow metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meet hematologic function criteria above",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below) based on institutional assessment:",
            "criterions": [
                {
                    "exact_snippets": "at least ONE of the following (lesions may have received prior radiation therapy as long as they meet the other criteria listed below) based on institutional assessment",
                    "criterion": "presence of at least one qualifying lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "institutional assessment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Platelet count ≥ 75,000/µL, transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count ≥ 75,000/µL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 75000,
                                "unit": "/µL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transfusion independent (no platelet transfusions within 7 days of blood draw documenting eligibility)",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence within 7 days prior to blood draw",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a diagnosis of neuroblastoma either by histologic verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of neuroblastoma",
                    "criterion": "neuroblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "histologic verification of neuroblastoma",
                    "criterion": "histologic verification of neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "demonstration of tumor cells in the bone marrow",
                    "criterion": "tumor cells in bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "increased urinary catecholamines",
                    "criterion": "urinary catecholamines",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "increased"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 31 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 31 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 31,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. SGPT (ALT) ≤ 135 U/L (≤ 3x ULN). Note that for ALT, the upper limit of normal for all sites is defined as 45 U/L.",
            "criterions": [
                {
                    "exact_snippets": "SGPT (ALT) ≤ 135 U/L (≤ 3x ULN)",
                    "criterion": "SGPT (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 135,
                                "unit": "U/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received the therapies indicated below after disease evaluation or within the specified time period prior to registration on this study as follows:",
            "criterions": [
                {
                    "exact_snippets": "must not have received the therapies indicated below after disease evaluation or within the specified time period prior to registration",
                    "criterion": "receipt of specified therapies",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "not after disease evaluation or within the specified time period prior to registration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2b) Persistent disease: A best overall response of partial response since diagnosis of high-risk neuroblastoma AND after at least 4 courses of induction therapy",
            "criterions": [
                {
                    "exact_snippets": "A best overall response of partial response since diagnosis of high-risk neuroblastoma",
                    "criterion": "best overall response since diagnosis of high-risk neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": "partial response"
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 courses of induction therapy",
                    "criterion": "number of induction therapy courses",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "courses"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2a) Refractory disease: A best overall response of no response/stable disease since diagnosis of high-risk neuroblastoma AND after at least 4 courses of induction therapy.",
            "criterions": [
                {
                    "exact_snippets": "A best overall response of no response/stable disease since diagnosis of high-risk neuroblastoma",
                    "criterion": "best overall response since diagnosis of high-risk neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "response type",
                            "expected_value": [
                                "no response",
                                "stable disease"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "after at least 4 courses of induction therapy",
                    "criterion": "number of induction therapy courses received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "courses"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2) If no prior history of recurrent/progressive disease since the diagnosis of high-risk neuroblastoma,",
            "criterions": [
                {
                    "exact_snippets": "no prior history of recurrent/progressive disease since the diagnosis of high-risk neuroblastoma",
                    "criterion": "history of recurrent/progressive disease since the diagnosis of high-risk neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. In addition to size, a lesion needs to meet ONE of the following criteria except for patients with parenchymal CNS lesions which will only need to meet size criteria:",
            "criterions": [
                {
                    "exact_snippets": "lesion ... needs to meet ONE of the following criteria except for patients with parenchymal CNS lesions which will only need to meet size criteria",
                    "criterion": "lesion (non-parenchymal CNS)",
                    "requirements": [
                        {
                            "requirement_type": "meets additional criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "parenchymal CNS lesions ... will only need to meet size criteria",
                    "criterion": "parenchymal CNS lesion",
                    "requirements": [
                        {
                            "requirement_type": "size criterion only",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3a) At least one soft tissue lesion that meets criteria for a TARGET lesion as defined by:",
            "criterions": [
                {
                    "exact_snippets": "At least one soft tissue lesion that meets criteria for a TARGET lesion",
                    "criterion": "soft tissue lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "target lesion criteria",
                            "expected_value": "meets criteria for a TARGET lesion"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal Function Patients must have adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age",
            "criterions": [
                {
                    "exact_snippets": "adequate renal function defined as age-adjusted serum creatinine ≤1.5 ULN for age",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "serum creatinine",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN for age"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii. If a patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Soft tissue lesions may be biopsied at any time point prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone)",
                    "criterion": "number of MIBG avid sites",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "sites"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "sites"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required",
                    "criterion": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in MIBG avid site",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of sites with confirmation",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Soft tissue lesions may be biopsied at any time point prior to enrollment",
                    "criterion": "biopsy of soft tissue lesions",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time point prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have high-risk neuroblastoma according to COG risk classification at the time of study registration. Patients whose disease was initially considered low or intermediate risk but then reclassified as high-risk neuroblastoma prior to enrollment also meet this criteria.",
            "criterions": [
                {
                    "exact_snippets": "Patients must have high-risk neuroblastoma according to COG risk classification at the time of study registration.",
                    "criterion": "neuroblastoma risk classification",
                    "requirements": [
                        {
                            "requirement_type": "risk group",
                            "expected_value": "high-risk"
                        },
                        {
                            "requirement_type": "classification system",
                            "expected_value": "COG"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of study registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients whose disease was initially considered low or intermediate risk but then reclassified as high-risk neuroblastoma prior to enrollment also meet this criteria.",
                    "criterion": "neuroblastoma risk reclassification",
                    "requirements": [
                        {
                            "requirement_type": "initial risk group",
                            "expected_value": [
                                "low",
                                "intermediate"
                            ]
                        },
                        {
                            "requirement_type": "reclassification",
                            "expected_value": "high-risk"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Biologic anti-neoplastics- agents not known to be associated with reduced platelet or ANC counts (including retinoids): must not have received within 7 days prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Biologic anti-neoplastics ... must not have received within 7 days prior to registration.",
                    "criterion": "biologic anti-neoplastic agents",
                    "requirements": [
                        {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days prior to registration"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "agents not known to be associated with reduced platelet or ANC counts (including retinoids)",
                    "criterion": "biologic anti-neoplastic agents not known to be associated with reduced platelet or ANC counts (including retinoids)",
                    "requirements": [
                        {
                            "requirement_type": "association with reduced platelet or ANC counts",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1) Recurrent/progressive disease after the diagnosis of high risk neuroblastoma at any time prior to enrollment - regardless of response to frontline therapy. (Note that this excludes patients initially considered low or intermediate risk that progressed to high risk disease but have not progressed after the diagnosis of high risk neuroblastoma).",
            "criterions": [
                {
                    "exact_snippets": "Recurrent/progressive disease after the diagnosis of high risk neuroblastoma at any time prior to enrollment",
                    "criterion": "disease status after high risk neuroblastoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "recurrent",
                                "progressive"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after the diagnosis of high risk neuroblastoma and prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "regardless of response to frontline therapy",
                    "criterion": "response to frontline therapy",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "any"
                        }
                    ]
                },
                {
                    "exact_snippets": "excludes patients initially considered low or intermediate risk that progressed to high risk disease but have not progressed after the diagnosis of high risk neuroblastoma",
                    "criterion": "progression after high risk neuroblastoma diagnosis in patients initially low/intermediate risk",
                    "requirements": [
                        {
                            "requirement_type": "progression after high risk diagnosis",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Normal fractional shortening (≥ 27%) documented by echocardiogram",
            "criterions": [
                {
                    "exact_snippets": "Normal fractional shortening (≥ 27%) documented by echocardiogram",
                    "criterion": "fractional shortening",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "echocardiogram"
                        },
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 27,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Cellular Therapy (e.g. modified T cells, NK cells, dentritic cells etc.): must not have received within 3 weeks and resolution of all toxicities.",
            "criterions": [
                {
                    "exact_snippets": "Cellular Therapy (e.g. modified T cells, NK cells, dentritic cells etc.): must not have received within 3 weeks",
                    "criterion": "cellular therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt within prior period",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "resolution of all toxicities",
                    "criterion": "toxicities",
                    "requirements": [
                        {
                            "requirement_type": "resolution",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. For MIBG avid tumors: lesion must be MIBG avid and meet one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "For MIBG avid tumors: lesion must be MIBG avid",
                    "criterion": "tumor lesion MIBG avidity",
                    "requirements": [
                        {
                            "requirement_type": "MIBG avidity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central Nervous System (CNS) Patients with a history of intraparenchymal or leptomeningeal based CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.",
            "criterions": [
                {
                    "exact_snippets": "Patients with a history of intraparenchymal or leptomeningeal based CNS disease must have no clinical or radiological evidence of active CNS disease at the time of study enrollment.",
                    "criterion": "active CNS disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "clinical",
                                "radiological"
                            ]
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the time of study enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Normal ejection fraction (≥ 55%) documented by either echocardiogram OR",
            "criterions": [
                {
                    "exact_snippets": "Normal ejection fraction (≥ 55%) documented by either echocardiogram",
                    "criterion": "ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 55,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "documentation_method",
                            "expected_value": [
                                "echocardiogram"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be ≥ 1 year and ≤31 years of age at the time of enrollment on the study.",
            "criterions": [
                {
                    "exact_snippets": "Patients must be ≥ 1 year and ≤31 years of age at the time of enrollment on the study.",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "year"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 31,
                                        "unit": "year"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3) Soft Tissue Sites",
            "criterions": [
                {
                    "exact_snippets": "Soft Tissue Sites",
                    "criterion": "soft tissue sites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematologic Function:",
            "criterions": [
                {
                    "exact_snippets": "Hematologic Function",
                    "criterion": "hematologic function",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "adequate"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study registration.",
            "criterions": [
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior chemotherapy",
                    "criterion": "recovery from acute toxic effects of prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior ... immunotherapy",
                    "criterion": "recovery from acute toxic effects of prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior ... radiotherapy",
                    "criterion": "recovery from acute toxic effects of prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have at least ONE of the following:",
            "criterions": [
                {
                    "exact_snippets": "at least ONE of the following",
                    "criterion": "presence of at least one criterion from a list",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 1 Year",
            "criterions": [
                {
                    "exact_snippets": "Must have minimum age of 1 Year",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "Year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Hematopoietic Stem Cell Transplant- none following myeloblative therapy within 6 weeks",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic Stem Cell Transplant- none following myeloblative therapy within 6 weeks",
                    "criterion": "hematopoietic stem cell transplant following myeloblative therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last procedure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Any other investigational agents (covered under another IND within 14 days",
            "criterions": [
                {
                    "exact_snippets": "Any other investigational agents (covered under another IND within 14 days",
                    "criterion": "use of other investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.",
            "criterions": [
                {
                    "exact_snippets": "Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.",
                    "criterion": "ambulatory status",
                    "requirements": [
                        {
                            "requirement_type": "definition for performance score",
                            "expected_value": "Patients unable to walk due to paralysis but up in a wheelchair are considered ambulatory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii. If a patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone) then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required. Bone lesions may be biopsied at any time point prior to enrollment.",
            "criterions": [
                {
                    "exact_snippets": "patient has only 1 or 2 MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone)",
                    "criterion": "number of MIBG avid sites",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "sites"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "sites"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one MIBG avid site present at the time of enrollment is required",
                    "criterion": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in MIBG avid site",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Bone lesions may be biopsied at any time point prior to enrollment",
                    "criterion": "biopsy of bone lesions",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time point prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Myelosuppressive chemotherapy: must not have received within 2 weeks prior to registration.",
            "criterions": [
                {
                    "exact_snippets": "Myelosuppressive chemotherapy: must not have received within 2 weeks prior to registration.",
                    "criterion": "myelosuppressive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recent administration",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3b) At least one non-target soft tissue lesion that is not measurable, but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment OR is MIBG avid on planar imaging.",
            "criterions": [
                {
                    "exact_snippets": "At least one non-target soft tissue lesion that is not measurable",
                    "criterion": "non-target soft tissue lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment",
                    "criterion": "soft tissue lesion biopsy result",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "neuroblastoma",
                                "ganglioneuroblastoma"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "is MIBG avid on planar imaging",
                    "criterion": "MIBG avidity on planar imaging",
                    "requirements": [
                        {
                            "requirement_type": "MIBG avidity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": "planar imaging"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. SIZE: Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm, or for discrete lymph nodes ≥ 15mm on short axis. Lesions meeting size criteria will be considered measurable.",
            "criterions": [
                {
                    "exact_snippets": "Lesion can be accurately measured in at least one dimension with a longest diameter ≥ 10 mm",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "longest diameter",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for discrete lymph nodes ≥ 15mm on short axis",
                    "criterion": "lymph node size",
                    "requirements": [
                        {
                            "requirement_type": "short axis diameter",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "mm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Radiation: must not have received small port radiation within 7 days prior to registration, large field radiation within 12 weeks, and 131I-MIBG therapy or other radiopharmaceutical within 6 weeks.",
            "criterions": [
                {
                    "exact_snippets": "must not have received small port radiation within 7 days prior to registration",
                    "criterion": "small port radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received ... large field radiation within 12 weeks",
                    "criterion": "large field radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have received ... 131I-MIBG therapy or other radiopharmaceutical within 6 weeks",
                    "criterion": "131I-MIBG therapy or other radiopharmaceutical",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "b. For MIBG non-avid tumors, patient must have biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment from soft tissue lesion (with or without FDG uptake) present at time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "MIBG non-avid tumors",
                    "criterion": "tumor MIBG avidity",
                    "requirements": [
                        {
                            "requirement_type": "MIBG avidity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment",
                    "criterion": "biopsy confirmation of neuroblastoma or ganglioneuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "from soft tissue lesion (with or without FDG uptake) present at time of enrollment",
                    "criterion": "soft tissue lesion presence at enrollment",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at time of enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Absolute Neutrophil count ≥750/µL",
            "criterions": [
                {
                    "exact_snippets": "Absolute Neutrophil count ≥750/µL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 750,
                                "unit": "µL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "i. No biopsy is required",
            "criterions": [
                {
                    "exact_snippets": "No biopsy is required",
                    "criterion": "biopsy",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients with skull-based tumors with direct intracranial extension are eligible as long as there are no neurologic signs or symptoms related to the lesion.",
            "criterions": [
                {
                    "exact_snippets": "skull-based tumors with direct intracranial extension",
                    "criterion": "skull-based tumor with direct intracranial extension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no neurologic signs or symptoms related to the lesion",
                    "criterion": "neurologic signs or symptoms related to the lesion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "NOTE: No short acting hematopoietic growth factors within 7 days of blood draw documenting eligibility and no long-acting hematopoietic growth factors within 14 days of blood draw documenting eligibility",
            "criterions": [
                {
                    "exact_snippets": "No short acting hematopoietic growth factors within 7 days of blood draw documenting eligibility",
                    "criterion": "short acting hematopoietic growth factor administration",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no long-acting hematopoietic growth factors within 14 days of blood draw documenting eligibility",
                    "criterion": "long acting hematopoietic growth factor administration",
                    "requirements": [
                        {
                            "requirement_type": "absence_within_timeframe",
                            "expected_value": {
                                "operator": "<",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a Lansky (≤ 16 years) or Karnofsky (> 16 years) score of ≥ 50 (Appendix I).",
            "criterions": [
                {
                    "exact_snippets": "Lansky (≤ 16 years) ... score of ≥ 50",
                    "criterion": "Lansky score",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Karnofsky (> 16 years) ... score of ≥ 50",
                    "criterion": "Karnofsky score",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Reproductive Function All females ≥ Tanner stage 2 and post-menarchal of childbearing potential must have a negative beta-HCG within 7 days prior to study registration. Males and females of reproductive age and childbearing potential must commit to using effective contraception for the duration of their participation.",
            "criterions": [
                {
                    "exact_snippets": "All females ≥ Tanner stage 2 and post-menarchal of childbearing potential must have a negative beta-HCG within 7 days prior to study registration.",
                    "criterion": "beta-HCG test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to study registration"
                        }
                    ]
                },
                {
                    "exact_snippets": "All females ≥ Tanner stage 2 and post-menarchal of childbearing potential",
                    "criterion": "female reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "Tanner stage",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "Tanner stage"
                            }
                        },
                        {
                            "requirement_type": "menarchal status",
                            "expected_value": "post-menarchal"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Males and females of reproductive age and childbearing potential must commit to using effective contraception for the duration of their participation.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "commitment to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of their participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pulmonary Function No evidence of dyspnea at rest",
            "criterions": [
                {
                    "exact_snippets": "No evidence of dyspnea at rest",
                    "criterion": "dyspnea at rest",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Total bilirubin ≤ 1.5 x ULN for age; and,",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 x ULN for age",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN for age"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. a) MIBG avid tumors: patients must meet one of the following criteria:",
            "criterions": [
                {
                    "exact_snippets": "MIBG avid tumors",
                    "criterion": "MIBG avid tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Strong inducers or inhibitors of CYP3A4",
            "criterions": [
                {
                    "exact_snippets": "Strong inducers or inhibitors of CYP3A4",
                    "criterion": "CYP3A4 modulating drugs",
                    "requirements": [
                        {
                            "requirement_type": "modulation_strength",
                            "expected_value": "strong"
                        },
                        {
                            "requirement_type": "modulation_type",
                            "expected_value": [
                                "inducer",
                                "inhibitor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "1b) For MIBG non-avid tumors, patients must have biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma from a lesion at any time prior to enrollment of at least one site (with or without FDG-PET uptake).",
            "criterions": [
                {
                    "exact_snippets": "MIBG non-avid tumors",
                    "criterion": "MIBG avidity of tumor",
                    "requirements": [
                        {
                            "requirement_type": "avidity",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma from a lesion at any time prior to enrollment of at least one site",
                    "criterion": "biopsy confirmation of neuroblastoma or ganglioneuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "neuroblastoma",
                                "ganglioneuroblastoma"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "any time prior to enrollment"
                        },
                        {
                            "requirement_type": "site_count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "a. Patients with recurrent/progressive or refractory disease: i. Must have at least one MIBG avid bone site on planar imaging OR ii. Must have > 2 avid bone lesions on SPECT. iii. A biopsy is not required unless the above imaging criteria are not met. b. Patients with persistent disease: i. If a patient has 3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone), then no biopsy is required.",
            "criterions": [
                {
                    "exact_snippets": "Patients with recurrent/progressive or refractory disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "recurrent",
                                "progressive",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one MIBG avid bone site on planar imaging",
                    "criterion": "MIBG avid bone site on planar imaging",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "> 2 avid bone lesions on SPECT",
                    "criterion": "avid bone lesions on SPECT",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lesions"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "A biopsy is not required unless the above imaging criteria are not met",
                    "criterion": "biopsy requirement for recurrent/progressive/refractory disease",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "not required if imaging criteria met"
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with persistent disease",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "persistent"
                        }
                    ]
                },
                {
                    "exact_snippets": "3 or more MIBG avid sites by planar or SPECT imaging (including soft tissue and/or bone)",
                    "criterion": "MIBG avid sites by planar or SPECT imaging",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "sites"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no biopsy is required",
                    "criterion": "biopsy requirement for persistent disease",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": "not required if 3 or more MIBG avid sites"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients with history of progressive disease while receiving therapy per ANBL1221.",
            "criterions": [
                {
                    "exact_snippets": "history of progressive disease while receiving therapy per ANBL1221",
                    "criterion": "progressive disease during ANBL1221 therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing/context",
                            "expected_value": "while receiving therapy per ANBL1221"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. The use of conventional doses of inhaled steroids for the treatment of asthma",
            "criterions": [
                {
                    "exact_snippets": "use of conventional doses of inhaled steroids for the treatment of asthma",
                    "criterion": "inhaled steroid use for asthma",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "conventional"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have been diagnosed with any other malignancy.",
            "criterions": [
                {
                    "exact_snippets": "must not have been diagnosed with any other malignancy",
                    "criterion": "diagnosis of other malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients on any other immunosuppressive medications (e.g., cyclosporine, tacrolimus) at the time of study registration.",
            "criterions": [
                {
                    "exact_snippets": "Patients on any other immunosuppressive medications (e.g., cyclosporine, tacrolimus) at the time of study registration.",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use at time of study registration",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are pregnant, breast feeding, or unwilling to use effective contraception during the study",
            "criterions": [
                {
                    "exact_snippets": "Patients who are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast feeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling to use effective contraception during the study",
                    "criterion": "willingness to use effective contraception",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.",
            "criterions": [
                {
                    "exact_snippets": "known history of human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known history of ... hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known history of ... hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with the safety monitoring requirements of the study",
                    "criterion": "ability to comply with safety monitoring requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Systemic Steroids and Immunosuppressive Medications",
            "criterions": [
                {
                    "exact_snippets": "Systemic Steroids",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Immunosuppressive Medications",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration.",
            "criterions": [
                {
                    "exact_snippets": "Patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration.",
                    "criterion": "hydrocortisone (or equivalent corticosteroid) requirement as premedication for blood product administration",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "mg/kg"
                            }
                        },
                        {
                            "requirement_type": "indication",
                            "expected_value": "premedication for blood product administration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are on hemodialysis.",
            "criterions": [
                {
                    "exact_snippets": "Patients who are on hemodialysis",
                    "criterion": "hemodialysis",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. The use of physiologic doses of steroids for patients with known adrenal insufficiency.",
            "criterions": [
                {
                    "exact_snippets": "physiologic doses of steroids",
                    "criterion": "steroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": "physiologic"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with known adrenal insufficiency",
                    "criterion": "adrenal insufficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with history of Grade 4 Allergic reactions to anti-GD2 antibody therapy or reactions that caused permanent discontinuation of therapy.",
            "criterions": [
                {
                    "exact_snippets": "history of Grade 4 Allergic reactions to anti-GD2 antibody therapy",
                    "criterion": "allergic reaction to anti-GD2 antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 4"
                        }
                    ]
                },
                {
                    "exact_snippets": "reactions that caused permanent discontinuation of therapy",
                    "criterion": "reaction to anti-GD2 antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "outcome",
                            "expected_value": "permanent discontinuation of therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with disease of any major organ system that would compromise their ability to withstand therapy.",
            "criterions": [
                {
                    "exact_snippets": "disease of any major organ system that would compromise their ability to withstand therapy",
                    "criterion": "disease of major organ system",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "impact on ability to withstand therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have undergone a prior allogeneic stem cell or solid organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "undergone a prior allogeneic stem cell or solid organ transplant",
                    "criterion": "history of allogeneic stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "undergone a prior allogeneic stem cell or solid organ transplant",
                    "criterion": "history of solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received pharmacologic doses of systemic steroids 7 days prior to study registration or likely to require them after study registration.",
            "criterions": [
                {
                    "exact_snippets": "received pharmacologic doses of systemic steroids 7 days prior to study registration",
                    "criterion": "systemic steroid use",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to study registration"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "pharmacologic"
                        }
                    ]
                },
                {
                    "exact_snippets": "likely to require them after study registration",
                    "criterion": "systemic steroid requirement",
                    "requirements": [
                        {
                            "requirement_type": "anticipated need after study registration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient declines participation in the NANT biology study and the site has not been granted a waiver from participation.",
            "criterions": [
                {
                    "exact_snippets": "Patient declines participation in the NANT biology study",
                    "criterion": "participation in the NANT biology study",
                    "requirements": [
                        {
                            "requirement_type": "declined",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "site has not been granted a waiver from participation",
                    "criterion": "waiver from participation in the NANT biology study",
                    "requirements": [
                        {
                            "requirement_type": "waiver granted",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with > Grade 2 diarrhea.",
            "criterions": [
                {
                    "exact_snippets": "Patients with > Grade 2 diarrhea",
                    "criterion": "diarrhea",
                    "requirements": [
                        {
                            "requirement_type": "severity_grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with an active or uncontrolled infection. Patients on prolonged antifungal therapy are still eligible if they are culture negative, afebrile, and meet other organ function criteria.",
            "criterions": [
                {
                    "exact_snippets": "Patients with an active or uncontrolled infection.",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "uncontrolled"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "<!-- -->",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Note: Exceptions are the following:",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}